RecruitingPhase 2NCT07228078
Open-Label Extension Protocol to SNK01-AD01 Study
An Open-Label Extension (OLE) Study to Evaluate the Long-Term Safety, Tolerability and Exploratory Efficacy of SNK01 in Participants With Alzheimer's Disease (Study SNK01-AD02)
Sponsor
NKGen Biotech, Inc.
Enrollment
30 participants
Start Date
Jun 30, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
Open-Label Extension Protocol to SNK01-AD01 Study
Eligibility
Min Age: 40 YearsMax Age: 85 Years
Inclusion Criteria4
- Participants will be considered eligible for participation in the study if all the following criteria are satisfied:
- The participant or their legally authorized representative must be willing and able to give their informed consent in writing and comply with the requirements of this study protocol. Informed consent for participants or their legally authorized representative and caregivers will be obtained before any trial-related activity. (Trial-related activities are any procedure that would not be performed during normal treatment of the subject).
- Participants must have a reliable study partner/caregiver (per investigator judgement for instance a family member, partner etc., guardian (must be always the same person)) who is in close contact with the patient, available on call and who is able to contribute to the assessment of the ratings of the functional endpoints at specific study visits. This person will be able to communicate in the language in which the participant is being assessed and should also serve as a backup contact for the study site.
- Participants previously completed participation in study SNK01-AD01.
Exclusion Criteria2
- Participants who fulfill any of the following criteria will not be recruited into the study:
- • Any participant whose safety the investigator considers to be at risk from this trial's intervention.
Interventions
BIOLOGICALSNK01
SNK01 is a novel cell-based, patient specific ex vivo expanded autologous natural killer (NK) cell, immunotherapeutic drug
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07228078
Related Trials
Novel Augmentation of DAOIB and Antioxidant for Early Dementia
NCT064675391 location
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
NCT06937229241 locations
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
NCT041233141 location
Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease
NCT071782101 location
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
NCT06585787278 locations